Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

1993 • 3,111 citations

Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

1992 • 1,063 citations

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

1999 • 983 citations

Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

1993 • 597 citations

Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

1995 • 537 citations

The LNCaP cell line--a new model for studies on human prostatic carcinoma.

1980 • 531 citations

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1998 • 496 citations

Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.

1990 • 485 citations

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1996 • 444 citations

Therapeutic Applications of Oligonucleotides

1992 • 438 citations

Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins

1999 • 438 citations

Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

1991 • 429 citations

Clusterin is a secreted mammalian chaperone

2000 • 365 citations

Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays

1999 • 356 citations

Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

1999 • 318 citations

Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.

1990 • 314 citations

Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death

2000 • 279 citations

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

1997 • 274 citations

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1998 • 266 citations

Active cell death in hormone-dependent tissues

1992 • 264 citations

Androgen‐repressed messages in the rat ventral prostate

1986 • 261 citations

Apolipoprotein J (clusterin) and Alzheimer's disease

2000 • 243 citations

Overexpression of Clusterin in Human Breast Carcinoma

2000 • 242 citations

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

2000 • 228 citations

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

1992 • 228 citations

Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin).

1995 • 224 citations

Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression

1999 • 222 citations

Induction of Apoptosis in Small-Cell Lung Cancer Cells by an Antisense Oligodeoxynucleotide Targeting the Bcl-2 Coding Sequence

1997 • 221 citations

Identification of Glycoprotein 330 as an Endocytic Receptor for Apolipoprotein J/Clusterin

1995 • 220 citations

Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer

1999 • 211 citations

Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer

1993 • 208 citations

Androgenic Induction of Prostate-specific Antigen Gene Is Repressed by Protein-Protein Interaction between the Androgen Receptor and AP-1/c-Jun in the Human Prostate Cancer Cell Line LNCaP

1997 • 203 citations

Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.

2000 • 202 citations

Bcl-xS Antagonizes the Protective Effects of Bcl-xL

1996 • 200 citations

Stress-induced transcription of the clusterin/apoJ gene

1997 • 196 citations

Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer.

1997 • 195 citations

Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis.

1993 • 194 citations

Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides

2000 • 185 citations

Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas

2000 • 179 citations

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

1999 • 176 citations

Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system.

1982 • 171 citations

Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer

1999 • 166 citations

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.

2000 • 154 citations

Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.

2000 • 154 citations

bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells

1997 • 153 citations

Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.

1996 • 152 citations

Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.

2002 • 152 citations

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

1999 • 136 citations

Overexpression of Insulin-Like Growth Factor Binding Protein-5 Helps Accelerate Progression to Androgen-Independence in the Human Prostate LNCaP Tumor Model through Activation of Phosphatidylinositol 3'-Kinase Pathway

2000 • 128 citations

Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells

1998 • 125 citations

Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin

2001 • 124 citations

Direct Transactivation of the Anti-apoptotic Gene Apolipoprotein J (Clusterin) by B-MYB

2000 • 112 citations

Clusterin Biogenesis Is Altered during Apoptosis in the Regressing Rat Ventral Prostate

1998 • 110 citations

Clusterin: A Role in Cell Survival in the Face of Apoptosis?

1996 • 107 citations

Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties

1998 • 102 citations

Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death.

1991 • 90 citations

Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model, CWR22-R

2001 • 76 citations

Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas

1994 • 73 citations

Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus.

1992 • 71 citations

Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.

1994 • 71 citations

Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model

2000 • 69 citations

Cytotoxic sensitivity to tumor necrosis factor-? in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin)

1999 • 67 citations

SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis

1991 • 67 citations

Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.

1999 • 58 citations

Clusterin and the kidney.

1995 • 54 citations

Immunohistochemical Analysis of Radical Prostatectomy Specimens After 8 Months of Neoadjuvant Hormonal Therapy.

1999 • 40 citations

Lack of Association between Enhanced TRPM-2/Clusterin Expression and Increased Apoptotic Activity in Sex-Hormone-Induced Prostatic Dysplasia of the Noble Rat

1998 • 39 citations

Clusterin in the Male Reproductive Tract

1998 • 28 citations

Presence of the long and the short forms of Bcl-X in several human and murine tissues.

1995 • 15 citations